PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50123C00056Advance the development of POTENT cross-reactive — Modex Therapeutics LLC

Modex Therapeutics LLC holds $103.5M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Feb 29, 2028 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Modex Therapeutics LLC

Recipient

Feb 29, 2028

PoP end

$103.5M

Obligated

541714

NAICS

AN13

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Modex Therapeutics LLC — $90

Contract facts

NONE

Contract number75A50123C00056

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentModex Therapeutics LLC

UEICDVMNSMRDTW8

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN13

Place of performanceNATICK, MA

Related solicitationBAA-18-100-SOL-0003

PoP end (current)Feb 29, 2028

PoP end (w/ options)Jan 18, 2030

Obligated$103.5M

ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND… is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Modex Therapeutics LLC. Estimated value $110M ($103.5M obligated). Current period of performance ends Feb 29, 2028 (potential Jan 18, 2030). Last award drew 1 bidder. Place of performance: NATICK, MA. Related solicitation BAA-18-100-SOL-0003.

ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND SEASONAL AND HIGHLY PATHOGENIC AVIAN INFLUENZA.

Recompete timing

Public

● Expiring in 540 days

Current PoP ends Feb 29, 2028 (540 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Aug 29, 2026.

Incumbent footprint

Public record

Modex Therapeutics LLC — $103.5M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$103.5M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50123C00056?

75A50123C00056 (Advance the development of POTENT cross-reactive) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $110M, currently held by Modex Therapeutics LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50123C00056?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50123C00056 to Modex Therapeutics LLC.

Who is the incumbent on 75A50123C00056?

Modex Therapeutics LLC is the incumbent with $103.5M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Feb 29, 2028.

When does Modex Therapeutics LLC’s 75A50123C00056 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 29, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75A50123C00056 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Dec 23, 2025